Rezivertinib - Beta Pharma
Alternative Names: BPI-7711; Rezivertinib mesylate - Beta PharmaLatest Information Update: 10 Jun 2026
At a glance
- Originator Beta Pharma
- Class Acrylamides; Amines; Antineoplastics; Dimethylamines; Indoles; Phenyl ethers; Pyrimidines; Small molecules
- Mechanism of Action ErbB receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
Most Recent Events
- 06 Sep 2025 Efficacy and adverse events data from the phase III RAZOR trials in Non-small cell lung cancer presented at the 26th World Conference on Lung Cancer (WCLC-2025)
- 23 Jul 2025 Launched for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in China (PO) - First global launch, before July 2025 (Beta Pharma pipeline, July 2025)
- 23 Jul 2025 Launched for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO), before July 2025 (Beta Pharma pipeline, July 2025)